Tryptamine Therapeutics stock analysis
Want to see AU:ENP full AI Analyst Report?
Tryptamine Therapeutics (ENP) Share Price & Analysis
ENP Stock Chart & Stats
- Day’s Range
- AUD 0.03 - AUD 0.03
- 52-Week Range
- AUD 0.03 - AUD 0.04
- Previous Close
- AUD 0.03
- Volume
- N/A
- Average Volume (3M)
- 1.20M
- Market Cap
- AUD 45.76M
- Enterprise Value
- AUD 48.24M
- Total Cash (Recent Filing)
- AUD 5.58M
- Total Debt (Recent Filing)
- AUD 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.43
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Positive equity and the absence of reported debt in recent annual reports reduce refinancing and interest-rate exposure. This gives the company greater financial flexibility than a similarly loss-making biotech, although ongoing losses still make preservation of that balance-sheet strength important.
Improved 2026 Performance
The improvement in annual net loss and the sharp reduction in operating and free cash outflows during 2026 indicate some cost containment. If sustained, this could extend the company’s operating runway and moderate the pace at which additional funding may be required.
Therapeutic Development Pipeline
Advancing multiple candidate programs through preclinical and clinical development creates potential for future product value beyond the company’s current financial profile. Success remains uncertain, but the therapeutic focus provides a defined platform for longer-term development and commercialization efforts.
Bears Say
No Meaningful Recurring Revenue
The absence of meaningful recurring revenue leaves the company dependent on development progress and external capital rather than operating sales. This weakens financial visibility over the next several quarters and means future research spending is not yet supported by a commercial revenue base.
Persistent Cash Burn
Consistently negative operating and free cash flow show that reported losses translate into actual cash consumption rather than being mainly non-cash accounting charges. Continued burn can reduce financial flexibility and require the company to manage spending carefully as programs advance.
Funding And Dilution Risk
Persistent losses and cash outflows increase the likelihood that additional external funding will be needed to sustain development. The history of debt in earlier years also shows that financing conditions can change, while new equity funding could dilute existing shareholders if losses persist.
Tryptamine Therapeutics News
Entropy Neurodynamics Issues Equity to Directors in Lieu of Cash Fees
The latest announcement is out from Tryptamine Therapeutics ( ($AU:ENP) ). Entropy Neurodynamics Limited, an ASX-listed company in the neurotechnology and neuroscience domain, structures director remuneration so that fees may
Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803
Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing precision-controlled psychedelic therapies, led by its IV-infused psilocin candidate TRP-8803 for
Entropy Neurodynamics to Showcase Psilocin Program in Investor Webinar
Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech focused on psilocin-based psychedelic-assisted therapies, is advancing proprietary formulations aimed at treating conditions with unmet
ENP FAQ
What was Tryptamine Therapeutics’s price range in the past 12 months?
What is Tryptamine Therapeutics’s market cap?
When is Tryptamine Therapeutics’s upcoming earnings report date?
How were Tryptamine Therapeutics’s earnings last quarter?
Is Tryptamine Therapeutics overvalued?
Does Tryptamine Therapeutics pay dividends?
What is Tryptamine Therapeutics’s EPS estimate?
How many shares outstanding does Tryptamine Therapeutics have?
What happened to Tryptamine Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tryptamine Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Tryptamine Therapeutics Stock Smart Score
Company Description
Tryptamine Therapeutics
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Alan Carroll
- Employees
- 4
- Website
- entropyneurodynamics.com
- Address
- Bio101 Financial Advisory Pty Ltd, Hawthorn East, VIC, 3123, AU
Tryptamine Therapeutics (ENP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 14 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 0 | 1 | 11 |










